-+ 0.00%
-+ 0.00%
-+ 0.00%

NANOBIOTIX ANNOUNCES FINAL DATA FROM PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) WITH IMMUNE CHECKPOINT INHIBITORS AS A 2L+ THERAPY IN ANTI-PD-1-RESISTANT PRIMARY CUTANEOUS MELANOMA

Reuters·10/24/2026 11:02:01